Inflammatory signals of cell death

FIREALARM investigates intercellular signaling in pyroptotic inflammation to uncover mechanisms driving chronic diseases and develop strategies for reversing sterile inflammation.

Subsidie
€ 1.991.250
2023

Projectdetails

Introduction

Inflammation is a natural mechanism to restore tissue homeostasis, and its deregulation causes human disease. The programmed cell death form pyroptosis elicits inflammation in a cell-autonomous and non-autonomous fashion by releasing cytokines and ‘danger’ signals.

Research Focus

Intriguingly, immune pathology independent of cytokines has alluded to unexplored signaling circuits between cells regulating pyroptotic inflammatory reactions. FIREALARM addresses the fundamental question of the physiological origin of inflammation using convergent system-wide, organismal, cell biological, and molecular approaches.

Hypothesis

We will test the central hypothesis that endogenous intercellular signaling proteins drive sterile inflammation and shift homeostatic stable to non-resolving chronic states.

Methodology

  1. Paracrine Activities: We will determine paracrine activities of pyroptosis by systematic, iterative ablation of molecule release from dying and perception pathways of sentinel cells.
  2. Signal Identification: In a complementary approach, we will identify inflammatory signals in vitro and in vivo by newly developed cell type-specific mass spectrometry-based secretomics technologies.

Goals

Holistic views of intercellular signaling proteins, their exposure, and modification will determine the molecular language orchestrating communication networks between cells. This will enable the recognition of signals initiating, amplifying, and resolving inflammation.

Expected Outcomes

We will achieve a new level of molecular and organismal understanding of intercellular circuits governing homeostasis and conceive strategies to revert chronic conditions. Emerging inflammatory cell death markers will stratify molecular etiology and outcome of patients with sterile inflammatory diseases.

Conclusion

Together, FIREALARM tackles the fundamental principles of sterile inflammation relevant for understanding the pathogenesis of chronic metabolic and age-related disorders.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.991.250
Totale projectbegroting€ 1.991.250

Tijdlijn

Startdatum1-1-2023
Einddatum31-12-2027
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITATSKLINIKUM BONNpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Network Synergies in Tissue Homeostasis and Stromal Prevention of Inflammatory Disease.

This project aims to uncover the mechanisms of tissue homeostasis and stromal biology to prevent inflammation onset, using advanced bioimaging and computational techniques for therapeutic advancements.

€ 1.499.514
ERC Consolid...

Negative Regulation of Inflammatory Responses Revealed with Camelid Nanobodies

The project aims to develop new cell biology tools to uncover intricate signaling networks that downregulate inflammation, focusing on the roles of NLRC3 and NLRX1 in controlling pro-inflammatory responses.

€ 1.997.828
ERC Advanced...

Spatio-temporal integration of skin inflammation

The project aims to elucidate spatio-temporal inflammasome signaling in keratinocytes to identify new therapeutic targets for inflammatory skin disorders like atopic dermatitis and psoriasis.

€ 2.499.188
ERC Advanced...

Architecture of Peripheral Neuroimmune Circuits and Synapses

This project aims to explore neuro-ILC2 interactions in vivo using innovative labelling tools to enhance understanding of neuroimmune dynamics and their implications for tissue health and disease.

€ 3.500.000
ERC Starting...

Understanding the functional role of Immune-related Intercellular Signalling Networks during tissue Development and Cancer

This project aims to uncover immune-related intercellular crosstalk in tissue development and cancer using single-cell RNA-sequencing and functional assays to identify novel therapeutic targets.

€ 2.025.000